Evaluation of fludarabine phosphate in patients with recurrent glioma.
Fifteen patients with recurrent primary brain tumors were treated with fludarabine phosphate. There were no responses seen. Toxicity was mild and primarily hematological. Fludarabine phosphate would appear to be ineffective in recurrent gliomas.
Cascino
T L
TL
Mayo Clinic, Rochester, Minnesota.
Brown
L D
LD
Morton
R F
RF
Everson
L K
LK
Marschke
R F
RF
Dinapoli
R P
RP
O'Fallon
J R
JR
D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001088:Arabinonucleotides / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D001084:Vidarabine Phosphate / Q000031:analogs & derivatives / Q000627:therapeutic use*
D000964:Antimetabolites, Antineoplastic; D001088:Arabinonucleotides; D001084:Vidarabine Phosphate; C042382:fludarabine phosphate